CN100588650C - 用于治疗hiv介导的疾病的非核苷逆转录酶抑制剂ⅰ - Google Patents

用于治疗hiv介导的疾病的非核苷逆转录酶抑制剂ⅰ Download PDF

Info

Publication number
CN100588650C
CN100588650C CN200480006480A CN200480006480A CN100588650C CN 100588650 C CN100588650 C CN 100588650C CN 200480006480 A CN200480006480 A CN 200480006480A CN 200480006480 A CN200480006480 A CN 200480006480A CN 100588650 C CN100588650 C CN 100588650C
Authority
CN
China
Prior art keywords
alkyl
compound
group
hydrogen
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN200480006480A
Other languages
English (en)
Chinese (zh)
Other versions
CN1759104A (zh
Inventor
J·P·杜恩
S·斯沃洛
Z·K·斯威尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1759104A publication Critical patent/CN1759104A/zh
Application granted granted Critical
Publication of CN100588650C publication Critical patent/CN100588650C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/13—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
CN200480006480A 2003-03-24 2004-03-22 用于治疗hiv介导的疾病的非核苷逆转录酶抑制剂ⅰ Expired - Lifetime CN100588650C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45713003P 2003-03-24 2003-03-24
US60/457,130 2003-03-24

Publications (2)

Publication Number Publication Date
CN1759104A CN1759104A (zh) 2006-04-12
CN100588650C true CN100588650C (zh) 2010-02-10

Family

ID=33098199

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200480006480A Expired - Lifetime CN100588650C (zh) 2003-03-24 2004-03-22 用于治疗hiv介导的疾病的非核苷逆转录酶抑制剂ⅰ

Country Status (20)

Country Link
US (2) US7208509B2 (https=)
EP (1) EP1608633B1 (https=)
JP (1) JP4708329B2 (https=)
KR (1) KR101122456B1 (https=)
CN (1) CN100588650C (https=)
AR (1) AR043673A1 (https=)
AU (1) AU2004224153B2 (https=)
BR (2) BRPI0408767B8 (https=)
CA (1) CA2518437C (https=)
CL (1) CL2004000590A1 (https=)
CO (1) CO5601029A2 (https=)
ES (1) ES2574580T3 (https=)
HR (1) HRP20050830A2 (https=)
IL (1) IL170343A (https=)
MX (1) MXPA05010210A (https=)
NO (1) NO334095B1 (https=)
NZ (1) NZ541829A (https=)
RU (1) RU2342367C2 (https=)
TW (1) TW200505441A (https=)
WO (1) WO2004085411A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ550857A (en) * 2004-04-01 2009-12-24 Aventis Pharma Inc 1,3,4-oxadiazol-2-ones as PPAR delta modulators
US8293778B2 (en) 2004-07-27 2012-10-23 Roche Palo Alto Llc Heterocyclic antiviral compounds
WO2006010545A1 (en) * 2004-07-27 2006-02-02 F. Hoffmann-La Roche Ag Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
CN101180280A (zh) * 2005-03-24 2008-05-14 弗·哈夫曼-拉罗切有限公司 作为杂环逆转录酶抑制剂的1,2,4-三唑-5-酮化合物
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
JP2009510013A (ja) * 2005-09-30 2009-03-12 エフ．ホフマン−ラ ロシュ アーゲー Ｎｎｒｔ阻害剤
WO2007045573A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
ATE545637T1 (de) * 2005-12-15 2012-03-15 Astrazeneca Ab Substituierte diphenylether, -amine, -sulfide und methane zur behandlung von atemwegserkrankungen
SG183007A1 (en) 2006-07-07 2012-08-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
CL2007002105A1 (es) * 2006-07-21 2008-02-22 Hoffmann La Roche Compuestos derivados de 2-[3-(3-cianofenoxi)(fenoxi o fenilsulfanil)]-n-fenil acetamida, inhibidores de la transcriptasa inversa del vih; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar u
CA2658984C (en) * 2006-08-16 2014-12-02 Joshua Kennedy-Smith Non-nucleoside reverse transcriptase inhibitors
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
PL3150586T3 (pl) * 2007-02-23 2020-06-01 Gilead Sciences, Inc. Modulatory farmakokinetycznych właściwości środków terapeutycznych
MX2009010932A (es) * 2007-04-09 2009-10-29 Hoffmann La Roche Inhibidores no nucleosidos de transcriptasa inversa.
BRPI0811645A2 (pt) 2007-05-30 2014-11-11 Hoffmann La Roche Inibidores de transcriptase reversa de não-nucleosídeo
BRPI0811988B1 (pt) * 2007-05-30 2021-05-25 F. Hoffmann-La Roche Ag Composto intermediário e processo para preparação de triazolonas
WO2008157273A1 (en) * 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
WO2008157330A1 (en) * 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
EP2170836A1 (en) * 2007-06-22 2010-04-07 F. Hoffmann-Roche AG Urea and carbamate derivatives as non-nucleoside reverse transcriptase inhibitors
US8492415B2 (en) * 2007-07-03 2013-07-23 Yale University Azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) in antiviral therapy (HIV)
RU2495878C2 (ru) * 2007-12-21 2013-10-20 Ф.Хоффманн-Ля Рош Аг Гетероциклические антивирусные соединения
SI2924034T1 (sl) * 2010-03-30 2017-05-31 Merck Canada Inc. Farmacevtski sestavek, ki obsega nenukleozidni inhibitor reverzne transkriptaze
CU23896B1 (es) * 2010-04-01 2013-05-31 Ct De Ingeniería Genética Y Biotecnología Método para inhibir la replicación del vih en células de mamíferos
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
CN104230929B (zh) * 2013-06-19 2015-11-18 华东师范大学 一种非核苷类hiv-1反转录酶抑制剂
WO2015153304A1 (en) 2014-04-01 2015-10-08 Merck Sharp & Dohme Corp. Prodrugs of hiv reverse transcriptase inhibitors
WO2026042788A1 (ja) * 2024-08-20 2026-02-26 塩野義製薬株式会社 複素環誘導体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274185A (en) 1963-10-08 1966-09-20 S E Massengill Company Phthalazine derivatives
US3813384A (en) 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
JP2593084B2 (ja) 1986-12-19 1997-03-19 メレルダウファーマスーティカルズ インコーポレーテッド ５−アリールー３ｈ−１，２，４−トリアゾールー３−オン類の神経変性障害の処置への用途
PH24094A (en) 1986-12-19 1990-03-05 Merrell Dow Pharma 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
US5436252A (en) 1986-12-19 1995-07-25 Merrell Dow Pharmaceuticals Inc. 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders
US4942236A (en) 1987-09-30 1990-07-17 American Home Products Corporation 2-aryl substituted pyridyl-containing phenyl sulfonamido compounds as antiallergic and antiinflammatory agents
US5103014A (en) 1987-09-30 1992-04-07 American Home Products Corporation Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives
US4826990A (en) 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US4966909A (en) 1989-12-20 1990-10-30 Merrell Dow Pharmaceuticals 4-benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-ones and their use as anticonvulsants
US5331002A (en) 1990-04-19 1994-07-19 Merrell Dow Pharmaceuticals Inc. 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful as memory enhancers
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5641796A (en) 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
WO1997040017A2 (en) 1996-04-19 1997-10-30 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
TW467902B (en) 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
PL223343B1 (pl) * 2000-10-30 2016-10-31 Kudos Pharm Ltd Zastosowanie związku, kompozycja farmaceutyczna zawierająca związek oraz pochodne ftalazynonowe
UA82048C2 (uk) 2000-11-10 2008-03-11 Эли Лилли Энд Компани Агоністи альфа-рецепторів, активованих проліфератором пероксисом
JP2002275165A (ja) * 2001-01-12 2002-09-25 Sumitomo Pharmaceut Co Ltd トリアゾール誘導体

Also Published As

Publication number Publication date
US7348345B2 (en) 2008-03-25
BRPI0408767B8 (pt) 2021-05-25
JP2006521319A (ja) 2006-09-21
RU2005132632A (ru) 2006-06-10
CO5601029A2 (es) 2006-01-31
NO334095B1 (no) 2013-12-09
AU2004224153A1 (en) 2004-10-07
US7208509B2 (en) 2007-04-24
CA2518437A1 (en) 2004-10-07
JP4708329B2 (ja) 2011-06-22
US20070179157A1 (en) 2007-08-02
AR043673A1 (es) 2005-08-03
CN1759104A (zh) 2006-04-12
CA2518437C (en) 2012-07-10
CL2004000590A1 (es) 2005-02-04
TW200505441A (en) 2005-02-16
NO20054264D0 (no) 2005-09-15
AU2004224153B2 (en) 2009-04-02
BR122016023941B1 (pt) 2021-10-13
RU2342367C2 (ru) 2008-12-27
BRPI0408767B1 (pt) 2017-10-31
EP1608633B1 (en) 2016-04-20
KR20050115294A (ko) 2005-12-07
EP1608633A1 (en) 2005-12-28
NZ541829A (en) 2008-11-28
NO20054264L (no) 2005-10-14
ES2574580T3 (es) 2016-06-20
HRP20050830A2 (en) 2006-09-30
BRPI0408767A (pt) 2006-03-28
IL170343A (en) 2014-03-31
KR101122456B1 (ko) 2012-04-26
US20040192704A1 (en) 2004-09-30
MXPA05010210A (es) 2005-11-23
WO2004085411A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
CN100588650C (zh) 用于治疗hiv介导的疾病的非核苷逆转录酶抑制剂ⅰ
CN100469769C (zh) 作为逆转录酶抑制剂的苄基-哒嗪酮
JP3290657B2 (ja) アンギオテンシンｉｉ拮抗剤として活性な酸性アラルキルトリアゾール誘導体
JP3295143B2 (ja) ベンズアニリド誘導体
JP4426660B2 (ja) ピラゾール誘導体、その製法および医薬としてのその使用
BRPI0809617A2 (pt) Inibidores não-nucleosídicos da transcriptase reversa
KR100673638B1 (ko) 아릴 알카노일피리다진류
WO2023016484A1 (zh) 磺酰胺衍生物、其制备方法及其在医药上的应用
CN1993332B (zh) 作为非核苷逆转录酶抑制剂的苄基三唑酮化合物
WO2022105852A1 (zh) 三嗪二酮类衍生物、其制备方法及其在医药上的应用
US7709469B2 (en) P2X7 receptor antagonists and methods of use
JP2008534456A (ja) ヘテロ環式逆転写酵素インヒビターとしての１，２，４−トリアゾール−５−オン化合物
WO2017040450A1 (en) Triazolopyridine inhibitors of myeloperoxidase
AU2002341218B2 (en) Benzotriazepines as gastrin and cholecystokinin receptor ligands
JP2003513962A (ja) ヘテロ環置換のジフェニルロイコトリエン拮抗薬
KR100803481B1 (ko) 비-뉴클레오사이드 역전사효소 억제제로서의벤질트라이아졸론 화합물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1089765

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1089765

Country of ref document: HK

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20100210